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Pharmacogenetics is the study of how individual genetics affect drug responses. 
Many studies investigated the impact of gene variation on the pharmacokinetic and 
pharmacodynamic of different drugs. This chapter gives an overview of the cur-
rent state of the pharmacological genetic aspects of these treatments. Drugs with 
genetic information to support product labeling, clinical guidelines, or significant 
mechanical effects are discussed. At this point, clinically relevant genetic variation 
in drug-metabolizing enzymes may reveal the dosage of certain drugs metabolized 
in the liver. In addition, genetic variation in immune genes can be tested to assess 
the risk of serious hypersensitivity reactions to certain drugs.
2. Pharmacogenetics and pharmacokinetics
Pharmacogenetic studies mainly focus on the difference in pharmacokinetic 
parameters after drug administration. These involve clinical investigation of 
different genes and their effect on biotransformation of drugs to metabolites; for 
example, tricyclic antidepressants were metabolized in different rates in different 
populations [1]. Most drugs used to treat neurological and psychiatric diseases are 
metabolized by the liver. Many genes encoding phase 1 (oxidation) and phase 2 
(combined) drug-metabolizing enzymes contain genetic polymorphisms, which 
are known to affect their metabolic activity. In addition, the pharmacokinetic pro-
file of certain drugs is highly affected by transport proteins that allow the absorp-
tion and distribution. These proteins are mainly expressed in hepatic tissue and 
in blood–brain barrier. The most common biotransformation enzymes are cyto-
chrome P450 (Phase 1), glucuronidase, and catechol/thiopurine methyltransferase 
(Phase 2). Furthermore, different neurological drugs are affected by transporters, 
such as P-glycoprotein.
Genetic variation in drug metabolism can alter the biotransformation of a 
particular drug and can occur due to a combination of inherited alleles from each 
parent. The results of the functioning of various combinations of drug-metaboliz-
ing enzyme alleles may vary slightly depending on the characteristics of the muta-
tion (e.g., fully inactivated enzyme, altered enzyme expression), but are generally 
maximal. Five categories are considered clinically relevant: (1) low- or no-enzyme 
activity, (2) medium-enzyme activity (reduced enzyme activity between normal 
and poor enzyme), (3) normal-enzyme activity (genetically unchanged enzyme 
activity), (4) fast-enzyme activity (with less increased enzyme activity compared 





Number of publications—PubMed citations (http://www.ncbi.nlm.nih.gov/pubmed) by date using the 
keyword “pharmacogenetics,” “pharmacogenomics,” or “clinical pharmacogenetics.”
3. Pharmacogenetics and pharmacodynamics
Genetic polymorphisms occurring in drug receptors or other biological targets 
are thought to be responsible for some of the observed variances in response and 
tolerance to treatment. For neurological and psychiatric conditions, this may 
include variations affecting the expression of the target receptor, the structure of 
the receptor, the arrangement of substance neurotransmitters, and second mes-
senger pathways. Beside the pharmacokinetic variation due to biotransformation, 
the pharmacodynamics of few drugs are mainly affected by genetic markers that are 
mentioned in the clinical guidelines. Three famous examples showing the effect of 
pharmacodynamic-related genes are hypersensitivity risks related to immunological 
genes, inborn metabolism variations due to gene variants, and antiepileptic drugs 
associated with life-threatening consequences. In addition, numerous studies have 
been performed to identify and characterize genetic variants related to pharmaco-
dynamics. In many cases, these signs may also be related to the risk of an underlying 
disease or illness. A simple example is the biopharmaceutical aspects of hypersensi-
tivity reactions [3].
4. Personalizing medicine
Personalized medicine was recognized in the early nineteenth century by Sir 
William Osler who studied the variation in drug responses among individuals. 
This concept evolved over years genomic information have been incorporated into 
patient’s clinical diagnosis and treatment. The major areas of applied research in 
this field involve identifying the genetic basis of common diseases, studying how 
genes and the environment interact to cause human disease, and using pharmaco-
genetic biomarkers to facilitate more effective drug therapy. Pharmacogenetics has 
become one of the leading and potentially most actionable areas of the personalized 
medicine paradigm, as evidenced by the increased availability of clinical pharma-




laboratories over the past few years. Moreover, the literature in pharmacogenetic 
studies over the past decade (Figure 1) has proved exponential growth beside FDA 
acknowledgement. A significant increase was observed starting from 2000 with 55 
publications till 2020 with 498 publications. Furthermore, the term personalized 
medicine (Figure 1) was also used from 2000 with 7 publications till 2020 with 
3009 publications (Figure 2) [4].
In conclusion, pharmacogenetics and personalized medicine showed a rapid 
growth over years with a great intention to apply the knowledge gained in clinical 
practice. Important genetic associations have been identified between variant geno-
types and drug response phenotypes that encouraged the FDA to revise drug labels 
to include relevant pharmacological genetic information and recommendations for 
some certain drugs. However, despite the availability of pharmacological genetic 
tests from Clinical Laboratory Improvement Amendments-approved laboratories, 
physician implementation of pharmacological genetic investigation has been 
unsatisfactory, maybe due to lack of awareness or inadequate professional guidance 
and limited coverage of testing coverage. Therefore, selected pharmacogenetic 
examples have been accepted into clinical practice and several others are currently 
being evaluated in randomized controlled trials.
Figure 2. 






Department of Pharmaceutics, College of Pharmacy and Drug Manufacturing,  
Misr University of Science and Technology (MUST), Giza, Egypt
*Address all correspondence to: islam.khalil@must.edu.eg
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 




[1] Hammer W, Sjöqvist F. Plasma levels 
of monomethylated tricyclic 
antidepressants during treatment with 
imipramine-like compounds. Life 
Sciences. 1967;6(17):1895-1903.  
DOI: 10.1016/0024-3205(67)90218-4
[2] Caudle KE, Dunnenberger HM, 
Freimuth RR, Peterson JF, Burlison JD, 
Whirl-Carrillo M, et al. Standardizing 
terms for clinical pharmacogenetic test 
results: Consensus terms from the 
Clinical Pharmacogenetics 
Implementation Consortium (CPIC). 
Genetics in Medicine. 2017;19(2): 
215-223. DOI: 10.1038/gim.2016.87
[3] Bishop JR. Pharmacogenetics. 
Handbook of Clinical Neurology. 
2018;147:59-73. DOI: 10.1016/
B978-0-444-63233-3.00006-3
[4] Scott SA. Personalizing medicine 
with clinical pharmacogenetics. 
Genetics in Medicine. 2011;13(12): 
987-995. DOI: 10.1097/
gim.0b013e318238b38c
References
